Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1987 1
1988 2
1989 1
1992 1
1993 3
1994 1
1995 2
1996 3
1997 7
1998 2
1999 6
2000 8
2001 6
2002 5
2003 9
2004 3
2005 3
2006 12
2007 18
2008 12
2009 8
2010 14
2011 15
2012 30
2013 28
2014 20
2015 32
2016 21
2017 18
2018 29
2019 27
2020 28
2021 29
2022 30
2023 23
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Localized Muscle Invasive Bladder Urothelial Carcinoma"
Page 1
NCCN Guidelines Insights: Bladder Cancer, Version 2.2022.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. Flaig TW, et al. J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041. J Natl Compr Canc Netw. 2022. PMID: 35948037
The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, pri …
The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients wi …
Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.
Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Teoh JY, et al. Nat Rev Urol. 2022 May;19(5):280-294. doi: 10.1038/s41585-022-00578-1. Epub 2022 Mar 31. Nat Rev Urol. 2022. PMID: 35361927 Review.
Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into the detrusor muscle layer. ...Various recurrence mechanisms have been described for NMIBC, such as undetected tumours upon cystoscopy, incomplete resection …
Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into the detrusor muscle …
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Laukhtina E, et al. Eur Urol Oncol. 2021 Dec;4(6):927-942. doi: 10.1016/j.euo.2021.10.003. Epub 2021 Nov 6. Eur Urol Oncol. 2021. PMID: 34753702 Free article. Review.
CONTEXT: During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commercially available. ...OBJECTIVE: To assess the diagnostic estimates of novel commercially available UBTs for diagnosis and surveillance of no …
CONTEXT: During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commer …
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
Alfred Witjes J, Max Bruins H, Carrión A, Cathomas R, Compérat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebianco V, Redlef J, Rink M, Rouanne M, Thalmann GN, Sæbjørnsen S, Veskimäe E, van der Heijden AG. Alfred Witjes J, et al. Eur Urol. 2024 Jan;85(1):17-31. doi: 10.1016/j.eururo.2023.08.016. Epub 2023 Oct 17. Eur Urol. 2024. PMID: 37858453 Review.
The importance of the presence or absence of urothelial carcinoma (UC) in the prostatic urethra is emphasised. Magnetic resonance imaging (MRI) of the bladder is superior to computed tomography (CT) for disease staging, specifically in differentiating T1 from …
The importance of the presence or absence of urothelial carcinoma (UC) in the prostatic urethra is emphasised. Magnetic resona …
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L. Lindskrog SV, et al. Nat Commun. 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. Nat Commun. 2021. PMID: 33863885 Free PMC article.
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. ...High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly as …
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneit …
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ, Sarfaty M, Teo MY, Ratna N, Duzgol C, Funt SA, Lee CH, Aggen DH, Regazzi AM, Chen Z, Lattanzi M, Al-Ahmadie HA, Brannon AR, Shah R, Chu C, Lenis AT, Pietzak E, Bochner BH, Berger MF, Solit DB, Rosenberg JE, Bajorin DF, Iyer G. Guercio BJ, et al. Clin Cancer Res. 2023 Nov 14;29(22):4586-4595. doi: 10.1158/1078-0432.CCR-23-1283. Clin Cancer Res. 2023. PMID: 37682528
EXPERIMENTAL DESIGN: Prospectively collected clinical data were integrated with institutional genomic data to define the landscape of FGFR2/3-altered urothelial carcinoma. To identify mechanisms of erdafitinib resistance, a subset of patients underwent prospective …
EXPERIMENTAL DESIGN: Prospectively collected clinical data were integrated with institutional genomic data to define the landscape of FGFR2/ …
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Sethi H, Aleshin A, Shi Y, Davarpanah N, Carter C, Bellmunt J, Mariathasan S. Powles T, et al. Eur Urol. 2024 Feb;85(2):114-122. doi: 10.1016/j.eururo.2023.06.007. Epub 2023 Jul 26. Eur Urol. 2024. PMID: 37500339
BACKGROUND: Interim results from IMvigor010 showed an overall survival (OS) benefit for adjuvant atezolizumab (anti-PD-L1) versus observation in patients with circulating tumor DNA (ctDNA)-positive muscle-invasive urothelial carcinoma (MIUC). OBJECTIVE …
BACKGROUND: Interim results from IMvigor010 showed an overall survival (OS) benefit for adjuvant atezolizumab (anti-PD-L1) versus observatio …
Imaging muscle-invasive and metastatic urothelial carcinoma.
Malayeri AA, Pattanayak P, Apolo AB. Malayeri AA, et al. Curr Opin Urol. 2015 Sep;25(5):441-8. doi: 10.1097/MOU.0000000000000208. Curr Opin Urol. 2015. PMID: 26222929 Free PMC article. Review.
PURPOSE OF REVIEW: Muscle-invasive bladder cancer (MIBC) comprises approximately one-third of bladder cancers and is associated with significant morbidity and mortality. Accurate staging of bladder cancer is essential because of significantly di …
PURPOSE OF REVIEW: Muscle-invasive bladder cancer (MIBC) comprises approximately one-third of bladder cancers an …
Pediatric urothelial bladder neoplasm.
Galiya R, Stanislav K, Jawdat J, Benjamin H, Boris C. Galiya R, et al. J Pediatr Urol. 2022 Dec;18(6):833.e1-833.e4. doi: 10.1016/j.jpurol.2022.06.026. Epub 2022 Jun 30. J Pediatr Urol. 2022. PMID: 35871900
OBJECTIVES: To report our experience and long-term follow-up data on pediatric patients with urothelial carcinoma of the urinary bladder. METHODS: In this retrospective two center study, we analyzed the perioperative and long-term follow-up data of nin …
OBJECTIVES: To report our experience and long-term follow-up data on pediatric patients with urothelial carcinoma of the ur …
Follow-up Management of Cystectomy Patients.
Reddy M, Kader K. Reddy M, et al. Urol Clin North Am. 2018 May;45(2):241-247. doi: 10.1016/j.ucl.2018.01.001. Urol Clin North Am. 2018. PMID: 29650139 Review.
Bladder cancer is the sixth leading cancer in the United States. Radical cystectomy is a lifesaving procedure for bladder cancer with or without muscle invasion. ...Functional complications after urinary diversion include bowel dysfunction, vita …
Bladder cancer is the sixth leading cancer in the United States. Radical cystectomy is a lifesaving procedure for bladder canc …
397 results